It's best to avoid sparking up a doobie on a spaceship, but there are other ways to consume substances in the cosmos.
Despite experts recommending that birth control be sold over the counter, the U.S. still treats the pill like it's 1960.
Paralyzing caution reveals the risks of vague anti-abortion legislation.
If approved, the drug could increase access to effective birth control.
Time for a new Operation Warp Speed?
The new company uses a simple approach to provide lifesaving drugs to consumers at radically discounted prices.
Doctors Adriane Fugh-Berman and Jeffrey Singer debate the harms of prescription opioids
The plan would reduce supply while increasing demand, resulting in harmful shortages.
Technological breakthroughs mean we'll never again have to suffer with disasters like the novel coronavirus—if politicians will get out of the way.
Psychiatrist Sally Satel on her eye-opening year at a clinic in Ironton, Ohio
"Economists are accustomed to thinking about tradeoffs," says economist and Nobel laureate Alvin Roth. "It appears that at least in some parts of the ethics community, they are not."
The Trump Administration's $765 Million Kodak Deal Is More Proof That 'Economic Nationalism' Is a Scam
The Trump administration's "economic nationalist" agenda is little more than a cronyist attempt at propping up domestic companies with taxpayer cash.
The Food and Drug Administration now says there is no evidence that any country attempted to cut off America's essential pharmaceuticals.
The Trump Administration Wants To Subsidize Domestic Drug Manufacturing. The First Contract Looks Like a $350 Million Grift.
A member of the five-month-old company's board has been touting bogus stats about America's supposed dependency on Chinese-made drugs.
Stocks rise steeply on good news about mRNA vaccines.
None have yet emerged that can clearly stem the tide of the ongoing pandemic.
The science is unsettled, and a new warning label would probably just confuse people.
The Right to Try movement, which recently became federal law, allows doctors to prescribe experimental treatments that haven't been approved for sale by regulators.
When and wherever public health conflicted with personal freedom, Gottlieb advocated for the former.
Plus: Tumblr porn filters catch company's own examples of permitted content and how the GOP learned to love bailouts.
"Our vision for a new, more transparent drug-pricing system does not rely on voluntary action," says HHS Secretary Alex Azar.
Plus: Parkour robots, price transparency for drugs, and Hillary Clinton defending Bill over the Lewinsky affair
Initiatives to curb drug-maker influence have endangered medical workers, patients, and the healthcare system.
Expect Fully Legal Weed Within 5 Years, Says Former Top Pharma Lobbyist and Congressman Billy Tauzin
He has been a Democrat, a Republican, a lobbyist, and a cancer survivor. Now he wants to end the war on weed.
It's still not clear whether pharmaceutical companies will work with patients outside the FDA's supervision.
From ripping families apart to nominating a torture-enabler as CIA director, the administration is calling the GOP's bluff, Reason editors argue.
Change drug prices by changing the market.
Making drug-company shareholders foot the bill for a public health crisis is flaky and counterproductive.
The drug regulator's clinical trials process for approving drugs needs a complete overhaul.
The change would put D.C. in line with a rapidly rising number of states allowing pharmacist-prescribed oral contraceptives.
Do the pain relief benefits of prescription opioids outweigh their addiction risks?
What will really keep drug (and any other) prices lower? Competition.
Reason editors talk immigration, affirmative action, and why the "Pharma Bro" witch hunt should concern everyone.
Senate approves bill giving some earlier access to treatment.
The pharmaceutical market is anything but free at present.
Make pharmaceutical competition great again.
Contrary to what The New York Times claims, the outcry over EpiPen prices has made them lower.
Understands how over-regulation is slowing down innovation in medicines and foods